Literature DB >> 28605636

A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.

Charles J Russell1, Bart G Jones2, Robert E Sealy2, Sherri L Surman2, John N Mason2, Randall T Hayden3, Ralph A Tripp4, Toru Takimoto5, Julia L Hurwitz6.   

Abstract

Human metapneumovirus (hMPV) infections pose a serious health risk to young children, particularly in cases of premature birth. No licensed vaccine exists and there is no standard treatment for hMPV infections apart from supportive hospital care. We describe the production of a Sendai virus (SeV) recombinant that carries a gene for a truncated hMPV fusion (F) protein (SeV-MPV-Ft). The vaccine induces binding and neutralizing antibody responses toward hMPV and protection against challenge with hMPV in a cotton rat system. Results encourage advanced development of SeV-MPV-Ft to prevent the morbidity and mortality caused by hMPV infections in young children.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunity; Metapneumovirus; Neutralizing antibodies; Recombinant vaccine; Respiratory virus; Sendai virus

Mesh:

Substances:

Year:  2017        PMID: 28605636      PMCID: PMC5551427          DOI: 10.1016/j.virol.2017.05.021

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  Localization of functional sites on the hemagglutinin-neuraminidase glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants.

Authors:  S D Thompson; A Portner
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

Review 2.  New Approaches for Immunization and Therapy against Human Metapneumovirus.

Authors:  Sherry C Wen; John V Williams
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

3.  Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates.

Authors:  Stéphane Biacchesi; Quynh N Pham; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Authors:  Bart G Jones; Robert E Sealy; Rajeev Rudraraju; Vicki L Traina-Dorge; Brad Finneyfrock; Anthony Cook; Toru Takimoto; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2011-11-23       Impact factor: 3.641

5.  Genomic analysis of four human metapneumovirus prototypes.

Authors:  Rohith Piyaratna; Sharon J Tollefson; John V Williams
Journal:  Virus Res       Date:  2011-06-28       Impact factor: 3.303

6.  The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity.

Authors:  John V Williams; Sharon J Tollefson; Joyce E Johnson; James E Crowe
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B.

Authors:  Xiaoyan Zhan; Julia L Hurwitz; Sateesh Krishnamurthy; Toru Takimoto; Kelli Boyd; Ruth A Scroggs; Sherri Surman; Allen Portner; Karen S Slobod
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

8.  Burden of human metapneumovirus infection in young children.

Authors:  Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Caroline B Hall; Peter G Szilagyi; Mary A Staat; Marika Iwane; Mila M Prill; John V Williams
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

9.  Human Metapneumovirus: An Important Cause of Respiratory Disease in Children and Adults.

Authors:  John V Williams
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

10.  Characterization of human metapneumoviruses isolated from patients in North America.

Authors:  Teresa C T Peret; Guy Boivin; Yan Li; Michel Couillard; Charles Humphrey; Albert D M E Osterhaus; Dean D Erdman; Larry J Anderson
Journal:  J Infect Dis       Date:  2002-05-03       Impact factor: 5.226

View more
  6 in total

Review 1.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

2.  Identification of key genes and signaling pathways during Sendai virus infection in vitro.

Authors:  Wenqiang Wei; Wanting Kong
Journal:  Braz J Microbiol       Date:  2018-12-17       Impact factor: 2.476

Review 3.  Prophylactic and therapeutic approaches for human metapneumovirus.

Authors:  Prashant Kumar; Mansi Srivastava
Journal:  Virusdisease       Date:  2018-10-20

Review 4.  Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

Review 5.  Human metapneumovirus - what we know now.

Authors:  Nazly Shafagati; John Williams
Journal:  F1000Res       Date:  2018-02-01

6.  Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.

Authors:  Felicia Scaggs Huang; David I Bernstein; Karen S Slobod; Allen Portner; Toru Takimoto; Charles J Russell; Michael Meagher; Bart G Jones; Robert E Sealy; Christopher Coleclough; Kristen Branum; Michelle Dickey; Kristen Buschle; Monica McNeal; Mat Makowski; Aya Nakamura; Julia L Hurwitz
Journal:  Hum Vaccin Immunother       Date:  2020-08-04       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.